Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frailty and Quality of Life in Low-Income, Uninsured Men With Prostate Cancer.

Urology·2026
Same author

Impact of comorbidity on patient reported outcome measures for men with localised prostate cancer.

BMC urology·2026
Same author

Disparities in health-related quality of life between Latino and White men with prostate cancer.

Journal of cancer survivorship : research and practice·2026
Same author

Predicting Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Model Development and Evaluation in an International Cohort Study.

Clinical genitourinary cancer·2026
Same author

Reply to Editorial Comment on "Fear of Cancer Recurrence Among Uninsured and Underrepresented Men With Prostate Cancer".

Urology·2026
Same author

Fear of Cancer Recurrence Among Uninsured and Underrepresented Men With Prostate Cancer.

Urology·2026

Related Experiment Video

Updated: Jul 15, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

The economic costs of early stage prostate cancer.

Christopher S Saigal1, Mark S Litwin

  • 1Department of Urology, University of California, Los Angeles, 90095-1738, USA.

Pharmacoeconomics
|October 17, 2002
PubMed
Summary

The economic burden of early stage prostate cancer is substantial, driven by screening, staging, and treatment costs. Optimizing healthcare spending requires evidence-based strategies and data from randomized controlled trials.

Area of Science:

  • Oncology
  • Health Economics
  • Public Health

Background:

  • Early stage prostate cancer presents significant economic challenges, particularly with aging populations in industrialized nations.
  • Estimated annual costs in the US range from $1.72 to $4.75 billion (1990).
  • Costs encompass screening, staging, and treatment, with population-based screening potentially costing $27.9 billion (1988).

Purpose of the Study:

  • To analyze the economic impact of early stage prostate cancer.
  • To identify key cost drivers in prostate cancer management.
  • To advocate for evidence-based strategies for cost-effective resource allocation.

Main Methods:

  • Review of economic cost data for prostate cancer screening, staging, and treatment.
  • Analysis of cost-effectiveness models for population-based screening programs.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

  • Discussion of the role of evidence-based staging and randomized controlled trials.

    • Main Results:

    • Significant economic burden associated with early stage prostate cancer.
    • Potential for substantial healthcare system charges from widespread screening.
    • Evidence-based staging strategies can reduce wasteful expenditure.

    Conclusions:

    • Rational allocation of healthcare resources for prostate cancer requires careful consideration of costs.
    • Data from randomized controlled trials are crucial for informed decision-making in prostate cancer screening and treatment.
    • Implementing evidence-based staging can lead to more efficient healthcare spending.